Report Company
NIBD (Private) Limited
NIBD is an institute one of its own kind in the region of South East Asia. The team of NIBD has experience of treating over 30,000 patients suffering from different blood disorders. After a long journey for more than a decade, NIBD team, under supervision of eminent professor of haematology, Dr. Tahir Shamsi has developed a highly skilled human resource in the sub division of haematology. NIBD’s vision is To develop a teaching institute with a strong research base where comprehensive clinical care will be provide locally, nationally as well as internationally to all deserving patients irrespective of their backgrounds.
State of the art facilities for the management of all primary and secondary blood disorders, teaching and training of students from different medical and paramedical fields, Professional development of staff, community awareness about hametological disorders and strong institutional commitment for research is our mission statement.
National and International recognition for serving the community by providing optimal clinical care and different unicenter & multicenter successful researches in the field of haematology and genetics is the stepping stone to achieve the goal of NIBD team. Trials such as Nnhf – Pk1 (Novonordisk Haemphilia Foundation), Microbiological Infection In Neutropenia Patients (Bosch), Jack 2 V617 F Mutation In Bcr/Abl And Cml, Fludarabine(Schering) have been completed successfully and some ongoing trials are Congenital F Vii Deficiency(Ster) (Dr Tahir Shamsi), Tra (Ramos) ITP (Idiopathic Thrombocytopenic Purpura) Phase IV Study, Randomised, Placebo Controlled, Multicentre Study to see efficacy and safety of eltrombopag in thrombocytopenic subjects, ACR (Asia Cml Registry), APBMTR (Asia Pacific Bone Marrow Transplantation Registry)100 Dayreport., CIBMTR(Centre For International Blood And Transplat Research) (Planned),CML Data(Updated 22-9-2011), Dengue Data (Updated 22-9-2011), Fungitell Data (Updated 22-9-2011) HLA-1 (Matched Data) Updated 7-8-2011), Hydroxyurea in B-Thalassemia etc.
State of the art facilities for the management of all primary and secondary blood disorders, teaching and training of students from different medical and paramedical fields, Professional development of staff, community awareness about hametological disorders and strong institutional commitment for research is our mission statement.
National and International recognition for serving the community by providing optimal clinical care and different unicenter & multicenter successful researches in the field of haematology and genetics is the stepping stone to achieve the goal of NIBD team. Trials such as Nnhf – Pk1 (Novonordisk Haemphilia Foundation), Microbiological Infection In Neutropenia Patients (Bosch), Jack 2 V617 F Mutation In Bcr/Abl And Cml, Fludarabine(Schering) have been completed successfully and some ongoing trials are Congenital F Vii Deficiency(Ster) (Dr Tahir Shamsi), Tra (Ramos) ITP (Idiopathic Thrombocytopenic Purpura) Phase IV Study, Randomised, Placebo Controlled, Multicentre Study to see efficacy and safety of eltrombopag in thrombocytopenic subjects, ACR (Asia Cml Registry), APBMTR (Asia Pacific Bone Marrow Transplantation Registry)100 Dayreport., CIBMTR(Centre For International Blood And Transplat Research) (Planned),CML Data(Updated 22-9-2011), Dengue Data (Updated 22-9-2011), Fungitell Data (Updated 22-9-2011) HLA-1 (Matched Data) Updated 7-8-2011), Hydroxyurea in B-Thalassemia etc.